Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on August 11, 2016, reporting events occurring on August 9, 2016. The filing details a sale-leaseback transaction involving company equipment.
Key Financial Metrics and Transaction Details
- Transaction Type: Sale-leaseback agreement with Essex Capital Corporation.
- Proceeds: Approximately $2,000,000 from the sale of equipment.
- Lease Term: 36 months on a net basis.
- Monthly Payments: Approximately $64,444.
- Use of Proceeds: Working capital and general corporate purposes.
- Financial Metrics: The filing does not provide current revenue, profit, cash flow, margins, or total debt figures.
Material Changes and Contractual Terms
The primary material change is the creation of a direct financial obligation via the lease agreement. Key terms include:
- Extension Option: The lease may be extended for an additional 12 months if the Company's first-half 2017 revenues exceed $16,000,000 and EBITDA exceeds $500,000.
- Purchase Option: Upon expiration, the Company may purchase the equipment at fair market value, capped at 15% of the original cost.
- Termination: If not purchased, the lease may extend month-to-month or the equipment may be returned.
Outlook, Risks, and Management Commentary
Management intends to utilize the $2 million proceeds to support working capital needs. The filing incorporates the full text of the Commercial Lease Agreement (Exhibit 10.1) and a press release (Exhibit 99.1) for complete details on rights and obligations. No specific risks or contingencies beyond the standard lease obligations are detailed in the summary text.
Investor Verification Checklist
- Verify the impact of the $64,444 monthly lease payment on future cash flow projections.
- Confirm the Company's ability to meet the 2017 revenue ($16M) and EBITDA ($500k) thresholds required for the lease extension.
- Review the full Commercial Lease Agreement (Exhibit 10.1) for covenants or default provisions not summarized here.
- Clarify the discrepancy between the metadata company name (Harrow, Inc.) and the filing registrant (Imprimis Pharmaceuticals, Inc.).